

CONFERENCE PROGRAM

Sunday, October 1

4:00 p.m.-6:00 p.m.

EDUCATIONAL SESSION

Ballroom 1

Please refer to Program and Proceedings supplement for more information.

6:15 p.m.-7:30 p.m.

WELCOME REMARKS AND OPENING KEYNOTE LECTURE

Ballroom 1

6:15 p.m.-6:30 p.m.

Welcome Remarks

6:30 p.m.-7:15 p.m.

Meeting the challenges in ovarian cancer

Joan S. Brugge, Harvard Medical School, Boston, MA

7:30 p.m.-9:30 p.m.

OPENING RECEPTION

King's Garden 4-5

Monday, October 2

7:00 a.m.-8:00 a.m.

CONTINENTAL BREAKFAST AND NETWORKING ROUNDTABLES

Sign up for roundtables at the AACR Registration Desk.

Ballroom 2

8:00 a.m.-10:00 a.m.

PLENARY SESSION 1: DNA DAMAGE AND REPAIR

Ballroom 1

Session Chairs: Ursula A. Matulonis, Dana-Farber Cancer Institute, Boston, MA, and **Roger A. Greenberg**, University of Pennsylvania, Philadelphia, PA

8:00 a.m.-8:20 a.m.

PARP inhibitors as single agents in combinations for ovarian cancer:

What lies ahead?

Ursula A. Matulonis

8:20 a.m.-8:40 a.m.

Inhibition of ATR overcomes the PARP inhibitor resistance of BRCA-deficient cancer cells

Lee Zou, MGH Cancer Center/Harvard Medical School, Boston, MA

8:40 a.m.-9:00 a.m.

Mitotic progression connects DNA damage to activation of antitumor immune responses

Roger A. Greenberg

9:00 a.m.-9:10 a.m.

Cyclin E: Targeting cell cycle dependencies in CCNE1-amplified tumors*

Kai Doberstein, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA

**Short talk from proffered abstract*

CONFERENCE PROGRAM

9:10 a.m.-9:20 a.m.	Exploring the effects of PARP inhibition on CHK1 activation as a potential determinant of synergy with CHK1 inhibition* Monicka Wielgos-Bonvallet, NYU Langone Medical Center, New York, NY
9:20 a.m.-10:00 a.m.	Plenary Session 1 Discussion
10:00 a.m.-10:30 a.m.	BREAK Grand Ballroom 1
10:30 a.m.-12:30 p.m.	PLENARY SESSION 2: METABOLIC CHANGES IN OVARIAN CANCER Ballroom 1 Session Chairs: Ernst R. Lengyel , University of Chicago, Chicago, IL, and Ahmed A. Ahmed , University of Oxford, Oxford, United Kingdom
10:30 a.m.-10:50 a.m.	Title to be announced Giulio F. Draetta, The University of Texas MD Anderson Cancer Center, Houston, TX
10:50 a.m.-11:10 a.m.	Stromal regulation of metastasis Ernst R. Lengyel
11:10 a.m.-11:30 a.m.	Targeting micrometastasis for the treatment of ovarian cancer Ahmed A. Ahmed
11:30 a.m.-11:50 a.m.	Kinase-mediated modulation of paclitaxel sensitivity in ovarian cancer Zhen Lu, The University of Texas MD Anderson Cancer Center, Houston, TX
11:50 a.m.-12:00 p.m.	Arginine deprivation as a potential targeted therapy for clear cell ovarian carcinoma* Jennifer Xiao Ye Ji, University of British Columbia, Vancouver, BC, Canada
12:00 p.m.-12:30 p.m.	Plenary Session 2 Discussion
12:30 p.m.-3:00 p.m.	FREE TIME (LUNCH ON OWN)
3:00 p.m.-5:00 p.m.	PLENARY SESSION 3: TUMOR MICROENVIRONMENT Ballroom 1 Session Chairs: Anil K. Sood , The University of Texas MD Anderson Cancer Center, Houston, TX, and Frances R. Balkwill , Barts Cancer Institute, London, United Kingdom
3:00 p.m.-3:20 p.m.	New directions in tumor microenvironment Anil K. Sood
3:20 p.m.-3:40 p.m.	Deconstructing and reconstructing the ovarian cancer microenvironment Frances R. Balkwill
3:40 p.m.-4:00 p.m.	Translating preclinical observations into trials addressing changes in the tumor microenvironment Robert L. Coleman, The University of Texas MD Anderson Cancer Center, Houston, TX

**Short talk from proffered abstract*

CONFERENCE PROGRAM

- 4:00 p.m.-4:10 p.m. **Tumor-derived indoleamine 2,3- dioxygenase regulates density of tumor infiltrating CD8+ T cells and myeloid-derived suppressor cells in a murine model of ovarian cancer***
Adaobi E. Amobi, Roswell Park Cancer Institute, Buffalo, NY
- 4:10 p.m.-4:20 p.m. **Nicotinamide N-methyltransferase metabolically reprograms the stroma to promote ovarian cancer metastasis***
Mark A. Eckert, University of Chicago, Chicago, IL
- 4:20 p.m.-5:00 p.m. **Plenary Session 3 Discussion**
- 5:00 p.m.-6:00 p.m.** **PANEL DISCUSSION: INNOVATIVE TRIAL DESIGN**
Ballroom 1
ARIEL3: A phase 3, randomized, double-blind study of rucaparib vs. placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC)*
Robert L. Coleman, The University of Texas MD Anderson Cancer Center, Houston, TX
Please refer to Program and Proceedings supplement for more information and additional panelists.
- 6:00 p.m.-8:30 p.m.** **POSTER SESSION A AND RECEPTION**
Ballroom 3-4

Tuesday, October 3

- 7:00 a.m.-8:00 a.m.** **CONTINENTAL BREAKFAST AND NETWORKING ROUNDTABLES**
Sign up for roundtables at the AACR Registration Desk.
Ballroom 2
- 8:00 a.m.-10:00 a.m.** **PLENARY SESSION 4: DRUG RESPONSE AND RESISTANCE TO THERAPY**
Ballroom 1
Session Chairs: David D. L. Bowtell, Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia, and **Gordon B. Mills**, The University of Texas MD Anderson Cancer Center, Houston, TX
- 8:00 a.m.-8:20 a.m. **Acquired chemotherapy resistance in high-grade serous ovarian cancer patients**
David D. L. Bowtell
- 8:20 a.m.-8:40 a.m. **Systems approach to drug development**
Gordon B. Mills
- 8:40 a.m.-9:00 a.m. **Exploiting synthetic lethality in the treatment of gynecologic cancers**
Christopher Lord, Cancer Research UK London Research Institute, London, United Kingdom

**Short talk from proffered abstract*

CONFERENCE PROGRAM

9:00 a.m.-9:10 a.m.	Combined MEK and BCL-2/XL inhibition as a potential drug combination for the treatment of high-grade serous ovarian cancer* Claudia Iavarone, Ludwig Center at Harvard, Harvard Medical School, Boston, MA
9:10 a.m.-9:20 a.m.	Longitudinal sampling of ctDNA reveals actionable mutations to optimize treatment of patients with high-grade serous ovarian cancer* Kaiyang Zhang, University of Helsinki, Helsinki, Finland
9:20 a.m.-10:00 a.m.	Plenary Session 4 Discussion
10:00 a.m.-10:30 a.m.	BREAK Grand Ballroom 1
10:30 a.m.-12:30 p.m.	PLENARY SESSION 5: PREVENTION AND EARLY DETECTION (Generously supported by Ovarcome) Ballroom 1 Session Chairs: Robert C. Bast, Jr. , The University of Texas MD Anderson Cancer Center, Houston, TX, and le-Ming Shih , Johns Hopkins Medical Institutes, Baltimore, MD
10:30 a.m.-10:50 a.m.	Early detection of ovarian cancer: An update Robert C. Bast, Jr.
10:50 a.m.-11:10 a.m.	PapGene, PapSEEK, and PapDREAMing for early detection of ovarian cancer le-Ming Shih
11:10 a.m.-11:30 a.m.	Physical and in silico methods for improving sensitivity of detection of ctDNA for personalized medicine in high-grade serous ovarian cancer James D. Brenton, University of Cambridge, Cambridge, United Kingdom
11:30 a.m.-11:40 a.m.	Derivation and validation of a serum diagnostic test for ovarian cancer using miRNA-seq* Kevin M. Elias, Brigham and Women's Hospital, Boston, MA
11:40 a.m.-11:50 p.m.	Breastfeeding protects against epithelial ovarian cancer: Results of the HOPE Study* Francesmary Modugno, University of Pittsburgh, Pittsburgh, PA
11:50 a.m.-12:30 p.m.	Plenary Session 5 Discussion
12:30 p.m.-3:00 p.m.	POSTER SESSION B AND LUNCH Ballroom 3-4
3:00 p.m.-5:00 p.m.	PLENARY SESSION 6: EXPLOITING VULNERABILITIES IN RARE TUMORS Ballroom 1 Session Chairs: David M. Gershenson , The University of Texas MD Anderson Cancer Center, Houston, TX, and David G. Huntsman , University of British Columbia, Vancouver, BC, Canada

*Short talk from proffered abstract

CONFERENCE PROGRAM

3:00 p.m.-3:20 p.m.	Progress and future directions in the management of low-grade serous cancer of the ovary David M. Gershenson
3:20 p.m.-3:40 p.m.	Granulosa cell and other rare ovarian cancers: Genomic-derived diagnostics and emergent management strategies David G. Huntsman
3:40 p.m.-4:00 p.m.	Therapeutic targeting of ARID1A mutation in ovarian cancer Rugang Zhang, The Wistar Institute, Philadelphia, PA
4:00 p.m.-4:20 p.m.	Small cell carcinomas of the ovary: Strengths and weaknesses Douglas A. Levine, New York University, New York, NY
4:20 p.m.-4:30 p.m.	The driver mutational landscape of ovarian squamous cell carcinomas arising in mature cystic teratoma* Darren Ennis, Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom
4:30 p.m.-5:00 p.m.	Plenary Session 6 Discussion
5:00 p.m.-6:00 p.m.	PANEL: FUNDING OPPORTUNITIES AND ADVOCACY GROUPS Ballroom 1 <i>Please refer to Program and Proceedings supplement for more information and panelists.</i>

Wednesday, October 4

7:00 a.m.-8:00 a.m.	CONTINENTAL BREAKFAST AND NETWORKING ROUNDTABLES <i>Sign up for roundtables at the AACR Registration Desk.</i> King's Garden 5
8:00 a.m.-10:00 a.m.	PLENARY SESSION 7: IMMUNOTHERAPY Ballroom 1 Session Chairs: Kunle Odunsi , Roswell Park Cancer Institute, Buffalo, NY, and David R. Spriggs , Memorial Sloan Kettering Cancer Center, New York, NY
8:00 a.m.-8:20 a.m.	Reprogramming the tumor microenvironment and T cells for ovarian cancer immunotherapy Kunle Odunsi
8:20 a.m.-8:40 a.m.	How does the immune system contend with intratumoral heterogeneity in ovarian cancer? Brad Nelson, BC Cancer Agency, Vancouver Island, BC, Canada
8:40 a.m.-9:00 a.m.	Translating fundamental immunobiology into adoptive T-cell therapy for ovarian cancer Daniel J. Powell, University of Pennsylvania, Philadelphia, PA

*Short talk from proffered abstract

CONFERENCE PROGRAM

9:00 a.m.-9:20 a.m.	Strategies for glycosylation-based immunotargeting of MUC16 David R. Spriggs
9:20 a.m.-9:30 a.m.	Epigenetic reprogramming promotes an immunogenic ovarian tumor microenvironment and synergizes with adoptive transfer of engineered T cells expressing NY-ESO-1 specific T-cell receptors* Li Shen, Roswell Park Cancer Institute, Buffalo, NY
9:30 a.m.-10:00 a.m.	Plenary Session 7 Discussion
10:00 a.m.-10:15 a.m.	BREAK Grand Ballroom 1
10:15 a.m.-12:15 p.m.	PLENARY SESSION 8: GENETICS AND MOLECULAR DRIVERS Ballroom 1 Session Chairs: Ronny I. Drapkin , University of Pennsylvania, Philadelphia, PA, and Robert K. Rottapel , Princess Margaret Cancer Centre, Toronto, ON, Canada
10:15 a.m.-10:35 a.m.	Replication road blocks in Cyclin E-amplified ovarian cancers Ronny I. Drapkin
10:35 a.m.-10:55 a.m.	Functional genetic architecture of serous ovarian cancer Robert K. Rottapel
10:55 a.m.-11:15 a.m.	Title to be announced Andy Futreal, The University of Texas MD Anderson Cancer Center, Houston, TX
11:15 a.m.-11:25 a.m.	TERT is frequently mutated in adult-type granulosa cell tumors of the ovary compared to other malignant sex cord-stromal tumors* Jessica A. Pilsworth, University of British Columbia, Vancouver, BC, Canada
11:25 a.m.-11:45 a.m.	CRISPR/Cas9-mediated <i>Trp53</i>, <i>Brca1</i>, <i>Brca2</i>, <i>Pten</i>, and <i>Nf1</i> knockout to generate improved murine models of ovarian high-grade serous carcinoma* Josephine Walton, The University of Glasgow, Glasgow, United Kingdom
11:45 a.m.-12:15 p.m.	Plenary Session 8 Discussion
12:15 p.m.	DEPARTURE

**Short talk from proffered abstract*